Neal Shore, MD, FACS, and Brian M. Shuch, MD, introduce themselves and discuss the growing incidence of kidney cancer, the general prognosis, and early signs and symptoms.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.